CN114271340A - Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof - Google Patents

Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof Download PDF

Info

Publication number
CN114271340A
CN114271340A CN202111447438.0A CN202111447438A CN114271340A CN 114271340 A CN114271340 A CN 114271340A CN 202111447438 A CN202111447438 A CN 202111447438A CN 114271340 A CN114271340 A CN 114271340A
Authority
CN
China
Prior art keywords
formula
powder
milk powder
content
intestinal
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202111447438.0A
Other languages
Chinese (zh)
Inventor
安晓楠
刘彪
孔小宇
王雯丹
吉塞拉·阿德里安娜·怀斯
司徒文佑
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Inner Mongolia Yili Industrial Group Co Ltd
Original Assignee
Inner Mongolia Yili Industrial Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Inner Mongolia Yili Industrial Group Co Ltd filed Critical Inner Mongolia Yili Industrial Group Co Ltd
Priority to CN202111447438.0A priority Critical patent/CN114271340A/en
Publication of CN114271340A publication Critical patent/CN114271340A/en
Pending legal-status Critical Current

Links

Images

Landscapes

  • Dairy Products (AREA)

Abstract

The invention provides formula milk powder containing lactose-N-tetrasaccharide and a preparation method and application thereof. Specifically, the invention provides application of lactose-N-tetrasaccharide in preparing formula milk powder for preventing intestinal leakage, wherein the total content of the lactose-N-tetrasaccharide in the formula milk powder is 100-2000mg/100g powder based on the total mass of the formula milk powder. The invention also provides formula milk powder containing lactose-N-tetrasaccharide and having the effect of preventing intestinal leakage and a preparation method thereof.

Description

Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof
Technical Field
The invention relates to formula milk powder containing breast milk oligosaccharide and a preparation method and application thereof, in particular to formula milk powder containing lactose-N-tetrasaccharide and having the effect of preventing intestinal leakage, a preparation method and related application thereof, and belongs to the technical field of formula milk powder.
Background
Intestinal leakage (leaky gut), refers to the phenomenon in which increased intestinal permeability causes harmful substances in the intestine, such as bacteria and toxins, to pass through the intestinal mucosa into other tissues, organs and blood circulation in the human body. Gut permeability is associated with gut barrier function, and normal gut permeability depends on the integrity of the gut mucosal barrier. The intestinal mucosal barrier is a complex multi-layered system including physical, chemical, biological and immunological barriers. The interaction of these barriers allows the intestinal tract to maintain a permeability balance, preventing the loss of water and electrolytes and the entry of antigens and microorganisms into the body, while allowing molecular exchange between the body and the environment and the absorption of nutrients in the food.
The intestinal physical barrier, which is the first line of defense against the external environment, occupies a central position in the intestinal barrier structure and is composed of intestinal epithelial cells and intercellular junctions. Intestinal cell permeability is largely divided into transepithelial or transcellular permeability and paracellular permeability. Cell bypass permeability is dependent on transport through interstitial spaces between cells. The intercellular junction includes tight junction, adhesion junction, desmosomes, etc., and most importantly, the tight junction is located at the apical end of the intestinal epithelial cell outer membrane and has a long and narrow band-like structure to block the intercellular space, thereby preventing macromolecular substances such as bacteria and toxins, etc. in the intestinal lumen from entering the blood circulation through the intercellular space. The intercellular tight junction structure has high dynamic stability, and its permeability determines the barrier function of the whole intestinal epithelial cell, and is regulated by intracellular and extracellular signals, and can be affected by diet, diseases, stress, etc.
The intestinal chemical barrier is mainly composed of the mucus layer, which can alter the sites of intestinal microorganisms, preventing them from coming into direct contact with the host intestinal tissue cells. In addition, some substances produced in the intestinal tract, such as bile salts, mucopolysaccharides, lysozyme and glycoproteins, can also play a role in chemical barriers.
The intestinal biological barrier is a micro-ecosystem with dynamic stability formed by intestinal symbiotic bacteria and a host, the intestinal symbiotic bacteria are attached to a mucous membrane layer on the surface of the intestinal tract of the host to form a microbial barrier formed by bacteria, and the intestinal biological barrier inhibits the colonization and the propagation of pathogenic bacteria through mechanisms such as competitive adhesion.
In the intestinal immunity barrier, intestinal tract-related lymphoid tissues play a role in juggling, wherein lymphocytes, macrophages and the like play a role in resisting pathogen invasion, and in intestinal tract immunity effector molecules, secretory immunoglobulin A (sIgA) plays a key role, is produced in an intestinal tract lamina propria and is secreted into an intestinal cavity after being processed by intestinal tract epithelial cells, can block adhesion of antigens such as bacteria, toxins and viruses on mucous membranes, and plays a role in clearing the antigens.
Intestinal leakage due to dysfunction of the intestinal barrier is a major potential cause of many health problems, including irritable bowel syndrome, headache, weight gain, hashimoto's thyroiditis, anxiety, depression, autoimmune diseases and allergies, among others. In particular, microbial toxins produced by the metabolism of the intestinal flora or other toxins entering with food enter the blood circulation through the intestinal wall with increased permeability ("intestinal leakage"), and cause various autoimmune symptoms by stimulating the autoimmune system or poisoning internal organs, thereby causing various diseases.
Compared with the infants fed by breast milk, the infants not fed by breast milk have poor intestinal development and are easy to have intestinal leakage.
Therefore, there is a need for a solution that can prevent the occurrence of intestinal leakage to promote intestinal health.
Disclosure of Invention
One object of the present invention is to provide a formula milk powder capable of preventing intestinal leakage.
The invention also aims to provide a preparation method of the formula milk powder.
The invention also aims to provide application of the formula milk powder.
The inventor finds in experimental research that breast milk oligosaccharide lactose-N-tetraose (LNT) can be used for preventing or improving intestinal leakage or intestinal barrier damage, is beneficial to improving intercellular intestinal permeability and intestinal barrier, improves intercellular gaps, and is particularly beneficial to maintaining infant intestinal health. Therefore, the lactose-N-tetrasaccharide is added into the milk powder, and the formula milk powder capable of preventing intestinal leakage and promoting intestinal health is provided.
lacto-N-tetraose, a hexasaccharide structure formed by lactose and tetraose, is a representative substance of oligosaccharides having a core sugar chain as a basic structure and not containing fucosyl or sialyl groups, which is generally commercially available through a microbial fermentation process and has the same structure as lacto-N-tetraose found in human milk.
Specifically, in one aspect, the invention provides the application of lactose-N-tetrasaccharide in preparing formula milk powder for preventing intestinal leakage, wherein the total content of the lactose-N-tetrasaccharide in the formula milk powder is 100-2000mg/100g powder based on the total mass of the formula milk powder.
On the other hand, the invention also provides the formula milk powder, which is prepared by adding lactose-N-tetrasaccharide into milk powder and has the effect of preventing intestinal leakage.
According to a particular embodiment of the invention, said prevention of intestinal leakage comprises improving intercellular intestinal permeability and/or intestinal barrier.
According to a particular embodiment of the invention, said prevention of intestinal leakage comprises reducing intercellular spaces.
According to a particular embodiment of the invention, the formula of the invention is a non-infant milk powder or an infant formula. Wherein the non-infant milk powder can be milk powder for children or milk powder for adults (including the middle-aged and the elderly).
According to a specific embodiment of the invention, in the formula milk powder, the total protein content of the formula milk powder is 10-20 g/100g based on the total mass of the formula milk powder; the fat content is 15-30 g/100 g; the carbohydrate content is 50-70 g/100 g. The total content of lactose-N-tetrasaccharide in the formula milk powder is 50-2000mg/100g powder. In some specific embodiments, the total content of lacto-N-tetraose in the formula may be 50-200mg per 100g of powder. In some specific embodiments, the total content of lactose-N-tetraose in the formula may be 500-1500mg/100g powder. In some specific embodiments, the total content of lactose-N-tetraose in the formula may be 1800-2000mg/100g powder.
According to a specific embodiment of the invention, the formula milk powder further contains linoleic acid and alpha-linolenic acid, wherein the content of the linoleic acid is 2700-4500 mg/100g and the content of the alpha-linolenic acid is 270-450 mg/100g based on the total mass of the formula milk powder.
In some specific embodiments of the invention, the formula powder of the invention is a formula powder for infants of 0-6 months, wherein the total protein content is 10-15 g/100g, the fat content is 23-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-60 g/100g based on the total mass of the formula powder. In some more specific embodiments, the total content of lactose-N-tetraose in the formula may be 1800-2000mg/100g powder, preferably 1900-2000mg/100g powder.
In some specific embodiments of the invention, the formula powder of the invention is a formula powder for infants with 6-12 months old, wherein the total protein content is 10-20 g/100g, the fat content is 20-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-65 g/100g based on the total mass of the formula powder. In some more specific embodiments, the total content of lactose-N-tetraose in the milk formula may be 500-1500mg/100g powder, such as 800-1200mg/100g powder, preferably 900-1100mg/100g powder.
In some specific embodiments of the invention, the formula powder is a formula powder for infants of 12-36 months, wherein the total protein content is 10-20 g/100g, the fat content is 15-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-70 g/100g, based on the total mass of the formula powder. In some more specific embodiments, the total content of lacto-N-tetraose in the formula may be from 50 to 200mg per 100g of powder, such as from 80 to 150mg per 100g of powder, preferably from 90 to 110mg per 100g of powder.
According to a specific embodiment of the present invention, the raw materials for providing total protein in the formula of the present invention comprise: raw milk (cow/sheep), whole milk powder (cow/sheep), skimmed milk powder (cow/sheep), whey protein powder (cow/sheep), desalted whey powder (cow/sheep), and one or more of beta-casein. Specifically, the formula milk powder comprises the following raw materials in parts by weight based on 1000 parts by weight: 0-3500 parts of raw milk (cow/sheep), 0-260 parts of whole milk powder (cow/sheep), 0-120 parts of whey protein powder (cow/sheep), 0-400 parts of skimmed milk powder (cow/sheep), and/or 0-600 parts of desalted whey powder (cow/sheep), and 0-40 parts of beta-casein.
According to a specific embodiment of the present invention, in the formula of the present invention, the raw material for providing fat comprises one or more of the following raw materials in parts by weight: 0-50 parts of corn oil, 0-65 parts of soybean oil, 0-100 parts of sunflower seed oil, 0-240 parts of 1, 3-dioleoyl-2-palmitic triglyceride, 0-30 parts of coconut oil, 0-85 parts of low erucic acid rapeseed oil and 0-20 parts of linseed oil.
According to a particular embodiment of the invention, the raw material for providing the lacto-N-tetraose in the formula of the invention is a commercially available food grade lacto-N-tetraose raw material.
According to a specific embodiment of the present invention, the raw materials for providing carbohydrates in the formula of the present invention comprise: 0-500 parts of lactose and/or the protein raw material containing lactose.
According to a particular embodiment of the invention, the formula of the invention, in particular of infant formula, may comprise, in addition to the above-mentioned components, the usual components of formula, for example, in the case of infant formula, one or more of nutrients, dietary fibres, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin.Preferably comprises a compound nutrient bag. In some preferred embodiments, the formula comprises 0-20 parts of nutrients including vitamins and minerals, or further optionally one or more of dietary fiber (fructooligosaccharides, galactooligosaccharides, polyfructose, etc.), inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, lactoferrin. The compound nutrient mainly comprises: compounding vitamins: vitamin A, vitamin D, vitamin E, and vitamin K1Vitamin B1Vitamin B2Vitamin B6Vitamin B12Nicotinic acid, folic acid, pantothenic acid, vitamin C, choline and biotin; compounding minerals: sodium, potassium, calcium, phosphorus, copper, iron, zinc, manganese, iodine, selenium, magnesium, potassium and derivatives thereof. The source, content and usage amount of the vitamins and minerals should meet the national standard and relevant regulations of milk powder or infant formula food.
On the other hand, the invention also provides a method for preparing the formula milk powder, which adopts a wet method or a dry-wet composite production process to mix lactose-N-tetrasaccharide with other raw materials in the formula to prepare the mother emulsified infant formula powder. The preparation process mainly comprises the following steps: preparing materials, homogenizing, concentrating, sterilizing, spray drying, and dry mixing to obtain the final product. In the present invention, the lacto-N-tetraose may be mixed together during compounding, or may be added during post-mixing or dry-mixing. The specific method conditions can be carried out according to the conventional method in the field of formula milk powder production.
In summary, the invention provides the application of the lactose-N-tetrasaccharide in preparing the food formula milk powder with the function of preventing intestinal leakage, in other words, the invention provides the application of the formula milk powder containing the lactose-N-tetrasaccharide in preparing the food formula milk powder with the function of preventing intestinal leakage. The formula milk powder can be used for preventing or improving intestinal leakage or intestinal barrier injury, is favorable for improving intercellular intestinal permeability and intestinal barrier, improves intercellular gaps, and is particularly favorable for maintaining infant intestinal health.
Drawings
Figure 1 shows the effect of lacto-N-tetraose on the molecular transport profile of FD 4.
Detailed Description
For a more clear understanding of the technical features, objects and advantages of the present invention, reference is now made to the following detailed description of the technical aspects of the present invention with reference to specific examples, which are intended to illustrate the present invention and not to limit the scope of the present invention.
Unless specifically defined otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the relevant art. Examples the raw material lacto-N-tetraose is from the supplier Jennewein and the content of lacto-N-tetraose is determined by methods conventional in the art. The operating conditions not specified in detail in the examples were carried out according to the usual procedures in the art.
Example 1
The embodiment provides a powdery infant formula with the age of 0-6 months, wherein the total protein content of the powdery infant formula is 10.5g/100g of powder, and the fat content of the powdery infant formula is 28.0g/100g of powder; the carbohydrate content was 52.5g/100g powder; the content of breast milk oligosaccharide (lactose-N-tetraose) is 1.8g/100g powder.
In the embodiment, the infant formula powder is prepared by compounding the following raw materials in parts by weight (1000 parts by weight):
1300 parts of raw goat milk, 350 parts of desalted whey powder, 220 parts of mixed vegetable oil (containing OPO), 220 parts of lactose, 25 parts of whey protein powder, 20 parts of lactose-N-tetrasaccharide raw material, 2.5 parts of compound vitamin and 8 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry-wet composite production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, dry mixing, and adding lactose-N-tetrasaccharide to obtain the final product.
Example 2
This example provides a powdered 6-12 month old older formula, which has a total protein content of 16.5g/100g powder and a fat content of 20.5g/100g powder; the carbohydrate content was 53.5g/100g powder; the content of breast milk oligosaccharide (lactose-N-tetraose) is 0.9g/100g powder.
In the embodiment, the infant formula powder is prepared by compounding the following raw materials in parts by weight (1000 parts by weight):
300 parts of desalted whey powder, 250 parts of skim milk powder, 170 parts of mixed vegetable oil (containing OPO structural fat), 100 parts of whole milk powder, 140 parts of lactose, 30 parts of whey protein powder, 10 parts of lactose-N-tetrasaccharide raw material, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry-wet composite production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, dry mixing, and adding lactose-N-tetrasaccharide to obtain the final product.
Example 3
The embodiment provides powdery formula goat milk powder for infants of 12-36 months old, wherein the total protein content of the powdery formula food is 13.0g/100g of the powder, and the fat content of the powdery formula food is 23.1g/100g of the powder; the carbohydrate content was 57.5g/100g powder; the content of breast milk oligosaccharide (lactose-N-tetraose) is 0.09g/100g powder.
The embodiment prepares the infant formula powder by compounding the following raw materials in parts by weight (1000 parts by weight):
2000 parts of raw milk, 325 parts of desalted whey powder, 220 parts of lactose, 150 parts of mixed vegetable oil (containing OPO structural fat), 45 parts of whey protein powder, 1 part of lactose-N-tetrasaccharide raw material, 3 parts of compound vitamin and 6 parts of compound mineral.
The infant formula powder of the embodiment is prepared by adopting a dry-wet composite production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, dry mixing, and adding lactose-N-tetrasaccharide to obtain the final product.
Compared with the infants fed by breast milk, the infants not fed by breast milk have poor intestinal development and are easy to have intestinal leakage.
Example 4
The embodiment provides a modified milk powder, wherein the total protein content of the powdery formula food is 17.5g/100g of powder, and the fat content of the powdery formula food is 18.0g/100g of powder; the carbohydrate content was 53.6g/100g powder; the content of breast milk oligosaccharide (lactose-N-tetraose) is 1.3g/100g powder.
The modified milk powder is prepared by compounding the following raw materials in parts by weight (1000 parts by weight):
3000 parts of raw milk, 460 parts of desalted whey powder, 65 parts of OPO structural fat, 50 parts of lactose, 50 parts of whey protein powder, 15 parts of lactose-N-tetrasaccharide raw material, 3 parts of compound vitamin and 6 parts of compound mineral substance.
The modified milk powder of the embodiment is prepared by adopting a dry-wet composite production process, and mainly comprises the following steps: preparing materials, preheating, homogenizing, concentrating, sterilizing, spray drying, dry mixing, and adding lactose-N-tetrasaccharide to obtain the final product.
Experiment on efficacy of lactose-N-tetrasaccharide in improving intestinal leakage
The experiment inspects the influence of different breast milk oligosaccharides and compositions thereof on the epithelial function of the small intestine under normal conditions, and shows that the intestinal permeability and the intestinal barrier between cells (the bypass permeability of cells) are improved through indexes such as the intestinal barrier and FD4 (fluorescein isothiocyanate dextran; FITC labeled dextran) molecular transport condition and the like.
Normal (non-invasive) condition
Caco-2 cells were cultured in DMEM medium in a transwell system for 21 days to simulate the small intestine epithelial cell layer. The test HMO or HMO composition (final concentration 0.1mg/mL in the culture system) was added and cultured for 24 hours, and then FD4 molecule (final surface concentration 250ug/mL) was added and the culture was continued. FD4 molecular transport was measured as three biological replicates at 24 hours of continued culture. A DMEM medium control was also set without any HMO or HMO composition tested.
Data analysis
The permeability data of FD4 for molecular transport was statistically analyzed using two-tailed paired T-test. Two groups were marked with an asterisk if they were significantly different and p < 0.05. Two asterisks indicate p < 0.01. Three asterisks indicate p < 0.001.
Results of the experiment
The results are shown in FIG. 1. The LNT provided by the invention has the advantages that the FD4 molecular transport (P <0.05) is remarkably reduced, the LNT provided by the invention is shown to improve the intercellular intestinal permeability (the intercellular intestinal permeability is reduced), and the intestinal barrier effect is improved, and the analysis reason is mainly to reduce the intercellular gap and improve the intercellular tightness, so that the tightness of the paracellular transport pathway is increased, and the intestinal leakage can be effectively reduced.

Claims (10)

1. The application of lactose-N-tetrasaccharide in preparing formula milk powder for preventing intestinal leakage, wherein the formula milk powder is non-infant milk powder or infant formula powder, and the total content of the lactose-N-tetrasaccharide in the formula milk powder is 50-2000mg/100g of powder based on the total mass of the formula milk powder.
2. The use according to claim 1, wherein the total protein content of the formula is 10-20 g/100g based on the total mass of the formula; the fat content is 15-30 g/100 g; the carbohydrate content is 50-70 g/100 g;
preferably, the formula milk powder also contains linoleic acid and alpha-linolenic acid, and based on the total mass of the formula milk powder, the content of the linoleic acid is 2700-4500 mg/100g, and the content of the alpha-linolenic acid is 270-450 mg/100 g.
3. The use of claim 1, wherein the formula is for infants of 0-6 months old, and comprises 10-15 g/100g of total protein, 23-30 g/100g of fat, 2700-4500 mg/100g of linoleic acid, 270-450 mg/100g of alpha-linolenic acid and 50-60 g/100g of carbohydrate, based on the total mass of the formula.
4. The use of claim 1, wherein the formula is for infants with 6-12 months old, and the total protein content is 10-20 g/100g, the fat content is 20-30 g/100g, the linoleic acid content is 2700-4500 mg/100g, the alpha-linolenic acid content is 270-450 mg/100g, and the carbohydrate content is 50-65 g/100g, based on the total mass of the formula.
5. The use of claim 1, wherein the formula powder is for infants of 12-36 months old, and comprises 10-20 g/100g of total protein, 15-30 g/100g of fat, 2700-4500 mg/100g of linoleic acid, 270-450 mg/100g of alpha-linolenic acid and 50-70 g/100g of carbohydrate, based on the total mass of the formula powder.
6. The use of any one of claims 1 to 5, wherein the formula further comprises one or more of nutrients, dietary fibers, inositol, taurine, L-carnitine, docosahexaenoic acid, arachidonic acid, lutein, nucleotides, and lactoferrin.
7. The use of claim 1, wherein the prevention of intestinal leakage comprises improving intercellular intestinal permeability and/or intestinal barrier.
8. The use of claim 1, wherein the prevention of intestinal leakage comprises reducing intercellular gaps.
9. The use of claim 1, wherein the lactose-N-tetraose is mixed with other raw materials in a formula powder by using a wet process or a dry-wet composite production process to prepare the formula powder.
10. Formula milk powder with intestinal leakage prevention effect, which is prepared by adding lactose-N-tetraose into milk powder according to the application of any one of claims 1-9.
CN202111447438.0A 2021-11-30 2021-11-30 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof Pending CN114271340A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN202111447438.0A CN114271340A (en) 2021-11-30 2021-11-30 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN202111447438.0A CN114271340A (en) 2021-11-30 2021-11-30 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof

Publications (1)

Publication Number Publication Date
CN114271340A true CN114271340A (en) 2022-04-05

Family

ID=80870415

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202111447438.0A Pending CN114271340A (en) 2021-11-30 2021-11-30 Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof

Country Status (1)

Country Link
CN (1) CN114271340A (en)

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335065A1 (en) * 2011-08-29 2014-11-13 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN112790250A (en) * 2020-12-04 2021-05-14 石家庄君乐宝乳业有限公司 Infant formula milk powder for promoting intestinal health and preparation method thereof
CN112868800A (en) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof
CN113163833A (en) * 2018-12-21 2021-07-23 雀巢产品有限公司 Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function
CN113194961A (en) * 2018-12-21 2021-07-30 格礼卡姆股份公司 Compositions and methods for promoting intestinal barrier healing
CN113194746A (en) * 2018-12-21 2021-07-30 雀巢产品有限公司 Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier
CN113519849A (en) * 2020-04-14 2021-10-22 内蒙古伊利实业集团股份有限公司 Breast milk oligosaccharide for improving intestinal tract resistance to escherichia coli infection and application thereof

Patent Citations (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140335065A1 (en) * 2011-08-29 2014-11-13 Abbott Laboratories Human milk oligosaccharides for preventing injury and/or promoting healing of the gastrointestinal tract
CN113662199A (en) * 2011-08-29 2021-11-19 雅培制药有限公司 Human milk oligosaccharides for preventing gastrointestinal damage and/or promoting gastrointestinal healing
CN113163833A (en) * 2018-12-21 2021-07-23 雀巢产品有限公司 Nutritional composition comprising a combination of 6' SL and LNT to improve gastrointestinal barrier function
CN113194961A (en) * 2018-12-21 2021-07-30 格礼卡姆股份公司 Compositions and methods for promoting intestinal barrier healing
CN113194746A (en) * 2018-12-21 2021-07-30 雀巢产品有限公司 Nutritional composition comprising a combination of human milk oligosaccharides to improve the gastrointestinal barrier
CN112868800A (en) * 2019-11-29 2021-06-01 内蒙古伊利实业集团股份有限公司 Infant formula milk powder containing breast milk oligosaccharide for improving immunity and preparation method thereof
CN113519849A (en) * 2020-04-14 2021-10-22 内蒙古伊利实业集团股份有限公司 Breast milk oligosaccharide for improving intestinal tract resistance to escherichia coli infection and application thereof
CN112790250A (en) * 2020-12-04 2021-05-14 石家庄君乐宝乳业有限公司 Infant formula milk powder for promoting intestinal health and preparation method thereof

Similar Documents

Publication Publication Date Title
RU2430631C2 (en) Probiotic oligosaccharides mixture and food product containing it
RU2607457C2 (en) Milk oligosaccharide-galactooligosaccharide composition for infant formula, containing soluble oligosaccharide fraction present in milk, and having low level of monosaccharides, and process to produce composition
CZ2003535A3 (en) Foodstuff preparation
CN110477129A (en) A kind of infant formula rich in milk fat globule membrane proteins and phosphatide
CN111616232A (en) Children milk powder for promoting bone growth and preparation method thereof
WO2016029113A1 (en) Methods of increasing endogenous production of beta-hydroxy-beta-methylbutyrate
NZ540775A (en) Nutritional composition comprising milk protein hydrolysate for use in the nutritional management and therapy of liver failure patients, inflammatory disease and hepatitis
Seki et al. Effect of lactulose on calcium and magnesium absorption: a study using stable isotopes in adult men
CN103623293A (en) Micro-ecological oral preparation
CN116076728B (en) Composition for promoting growth of bifidobacteria
CN114128767B (en) Milk protein partially hydrolyzed hypoallergenic infant formulas containing breast milk oligosaccharides
CN112533494A (en) Treatment or prevention of gestational diabetes using polar lipids
CN114145354B (en) Formula milk powder containing breast milk oligosaccharide and preparation method and application thereof
AU2017376227B2 (en) Nutritional compositions containing butyrate and/or lactoferrin and uses thereof
WO2022266058A1 (en) Methods and compositions for treating gas
CN114145353A (en) Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN114208893A (en) Formula milk powder capable of improving intestinal microenvironment health and preparation method and application thereof
CN111491638A (en) Composition comprising at least one N-acetylated oligosaccharide and at least one fucosylated oligosaccharide for promoting digestibility in infants and young children
CN114271340A (en) Formula milk powder containing lactose-N-tetrasaccharide and preparation method and application thereof
US20210236528A1 (en) Composition comprising isomers of inositol and its use
CN114451453B (en) Breast milk oligosaccharide composition for preventing intestinal leakage and application thereof
US20220400729A1 (en) Synergistic combination of butyric-acid-producing prebiotics and probiotics
EP1523311B1 (en) Calcium lactate and whey permeate for lowering the triglyceride level
Dong et al. Research progress of probiotics and prebiotics in ajuvant therapy for diseases and prospect of their application in functional foods
CN114452295A (en) Use of lacto-N-tetraose for preventing intestinal leakage

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20220405